Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

47.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
47.1K
Retroviruses02:33

Retroviruses

12.7K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
12.7K
Subviral Agents01:29

Subviral Agents

144
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
144

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era.

The Journal of antimicrobial chemotherapy·2025
Same author

CD4 T cell counts are inversely correlated with anti-gp120 cluster A antibodies in antiretroviral therapy-treated PLWH.

EBioMedicine·2025
Same author

Addressing late HIV presentation: the current knowledge and unmet needs.

Expert review of anti-infective therapy·2025
Same author

Time fixes everything, but not always: 10 years of persistent PI mutations in the absence of pharmacological pressure-a case report.

The Journal of antimicrobial chemotherapy·2025
Same author

Prevalence and Incidence of Metabolic Syndrome in People With HIV Receiving Cabotegravir and Rilpivirine.

Journal of acquired immune deficiency syndromes (1999)·2025
Same author

Risk of Cancer in People With HIV Experiencing Varying Degrees of Immune Recovery With Sustained Virological Suppression on Antiretroviral Treatment for More Than 2 Years: An International, Multicenter, Observational Cohort.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025

Related Experiment Video

Updated: Sep 23, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.6K

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.

Sorana Segal-Maurer1, Edwin DeJesus1, Hans-Jurgen Stellbrink1

  • 1From NewYork-Presbyterian Queens, Flushing, NY (S.S.-M.); Orlando Immunology Center, Orlando (E.D.), and Fort Lauderdale (G.J.R.) - both in Florida; Infektionsmedizinisches Centrum Hamburg, Hamburg, Germany (H.-J.S.); Vita-Salute University, San Raffaele Scientific Institute, Milan (A.C.); Prism Health North Texas (G.I.S.) and North Texas Infectious Diseases Consultants (M.B.) - both in Dallas; Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand (K.S.); Ruane Clinical Research Group, Los Angeles (P.J.R.), and Gilead Sciences, Foster City (H.W., N.A.M., H.D.-S., R.H.H., D.M.B., M.S.R., J.M.B.) - both in California; the University of Paris and the Department of Infectious Diseases, St. Louis-Lariboisière Hospitals, Assistance Publique-Hôpitaux de Paris, Paris (J.-M.M.); and AlloVir, Cambridge, MA (D.M.B.).

The New England Journal of Medicine
|May 11, 2022
PubMed
Summary

Lenacapavir, a novel capsid inhibitor, significantly reduced viral load in patients with multidrug-resistant HIV-1. This long-acting injectable offers a new treatment option for difficult-to-treat HIV-1 infections.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.0K
A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
07:22

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

6.6K

Related Experiment Videos

Last Updated: Sep 23, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.6K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.0K
A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
07:22

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

6.6K

Area of Science:

  • Infectious Diseases
  • Virology
  • Pharmacology

Background:

  • Multidrug-resistant human immunodeficiency virus type 1 (HIV-1) presents limited therapeutic options.
  • Lenacapavir is a pioneering capsid inhibitor demonstrating significant antiviral activity in early studies.

Purpose of the Study:

  • To evaluate the efficacy and safety of lenacapavir in patients with multidrug-resistant HIV-1.
  • To assess lenacapavir's viral load reduction and long-term maintenance of viral suppression.

Main Methods:

  • Phase 3 trial with two cohorts for multidrug-resistant HIV-1 patients.
  • Cohort 1: Oral lenacapavir/placebo for 14 days, followed by subcutaneous lenacapavir (6-monthly) vs. placebo group receiving oral then subcutaneous lenacapavir.
  • Cohort 2: Open-label oral lenacapavir for 14 days, followed by 6-monthly subcutaneous lenacapavir. Both cohorts received optimized background therapy.

Main Results:

  • In cohort 1, 88% of patients on lenacapavir achieved a viral load reduction of at least 0.5 log10 copies/mL by day 15, versus 17% on placebo.
  • At week 26, viral load <50 copies/mL was achieved by 81% (cohort 1) and 83% (cohort 2).
  • Lenacapavir was well-tolerated; no serious adverse events were reported. Resistance mutations emerged in 8 patients.

Conclusions:

  • Lenacapavir demonstrated superior viral load reduction compared to placebo in multidrug-resistant HIV-1 patients.
  • The long-acting injectable lenacapavir provides an effective new treatment strategy for HIV-1.
  • Lenacapavir shows promise for long-term viral suppression in HIV-1 management.